Angiotensin II receptor blockers and cardiorenal risk management: Irbesartan status
The article tells about the role of angiotensin II receptor blockers in risk management of cardiovascular and renal complications in diabetes mellitus. The results of clinical trials of Irbesartan (Aprovel®) are demonstrated.
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artigo |
| Langue: | Russo |
| Publié: |
Remedium Group LLC
2013-12-01
|
| Collection: | Медицинский совет |
| Sujets: | |
| Accès en ligne: | https://www.med-sovet.pro/jour/article/view/1100 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|